Immune deficiencies, infection, and systemic immune disorders
The long road to optimal management for chronic granulomatous disease

https://doi.org/10.1016/j.jaci.2013.08.035Get rights and content

References (14)

There are more references available in the full text version of this article.

Cited by (9)

  • Advances in basic and clinical immunology in 2013

    2014, Journal of Allergy and Clinical Immunology
    Citation Excerpt :

    The authors emphasized that severity of clinical presentation is associated with residual nicotinamide adenine dinucleotide phosphate but not with the specific gene that is mutated and should be considered for assessment of prognosis and use of HSCT. Notarangelo56 commented on the long road to optional management of patients with CGD and predicted better outcomes with improvement in methods of HCST and gene therapy. Horn and Cowan57 reviewed the published literature concerning outcomes of HSCT for SCID.

  • Gut microbiota–host interactions in inborn errors of immunity

    2021, International Journal of Molecular Sciences
View all citing articles on Scopus

Disclosure of potential conflict of interest: L. D. Notarangelo is on advisory boards for the Immune Disease Institute and Meyer Hospital Florence; is employed by Children's Hospital Boston; has received grants from the National Institutes of Health, the March of Dimes, and the Jeffrey Modell Foundation; and has received royalties from UpToDate.

View full text